Weekly cisplatin achieves 84% five-year survival in p16-positive oropharyngeal cancer

Weekly cisplatin 40 mg/m² with definitive RT yielded 84% five-year survival and 80% progression-free survival in 103 p16-positive oropharyngeal cancer patients.

KEY POINTS

  • This retrospective single-center study evaluated 103 patients with p16-positive oropharyngeal squamous cell carcinoma receiving definitive chemoradiotherapy with weekly cisplatin 40 mg/m² at Townsville University Hospital, Australia, between 2015 and 2021. Median follow-up was 56 months; 75 patients (73%) lived in rural or remote areas, 38 (37%) had T3–T4 disease, and 90 (87%) had N2–N3 disease according to AJCC seventh edition staging.
  • Radiotherapy was delivered predominantly using VMAT, with 93/103 patients (90.3%) receiving 70 Gy in 35 fractions and 7 (6.8%) receiving 69.96 Gy in 33 fractions. Three additional patients discontinued RT after receiving at least a biologically equivalent dose of 66 Gy in 2-Gy fractions. Cisplatin was scheduled weekly for six cycles, targeting a cumulative dose of 240 mg/m², with additional administration in week seven when clinically indicated.
  • At five years, overall survival was 84% (95% CI 76–92%) and progression-free survival was 80% (95% CI 72–89%). Corresponding two-year outcomes were 94% OS and 90% PFS, while only 4/103 patients (4%) developed locoregional recurrence and 5/103 (5%) developed distant metastatic recurrence during follow-up.
  • Among 57 patients classified as low risk according to Ang criteria, five-year OS was 86% and PFS was 87%, with no locoregional recurrences and a five-year distant failure rate of 6%. These outcomes are encouraging, but they do not demonstrate that weekly cisplatin is equivalent to three-weekly high-dose cisplatin because both regimens were not compared within this study.
  • The 46 intermediate-risk patients experienced five-year OS of 81% and PFS of 71%, with locoregional and distant failure rates of 10% and 7%, respectively. Progression-free survival was significantly worse than in the low-risk group (71% vs 87%; p=0.04), while the overall survival difference was not statistically significant (p=0.36), suggesting that smoking history and nodal burden remain relevant prognostic factors.
  • Patients with T4 or N3 disease (n=24) had substantially worse outcomes despite excellent observed locoregional control. Five-year OS and PFS were both 55%, while the estimated distant failure rate reached 31% without recorded locoregional recurrence. Compared with the remaining patients, T4/N3 disease was associated with worse OS (HR 4.36, 95% CI 1.61–11.8; p=0.0038), emphasizing the importance of distant progression in this higher-risk subgroup.
  • The median cumulative cisplatin dose was 240 mg/m², and 83/103 patients (81%) received at least 200 mg/m². Five-year OS did not differ significantly between patients receiving ≥200 versus <200 mg/m² (86% vs 78%; p=0.76), although the lower-dose group was small. Treatment toxicity led to cisplatin dose reductions in 8%, delays in 13%, and early discontinuation in 30%, most commonly related to cytopenias, mucositis, renal dysfunction or infection.

CLINICAL TAKEAWAY

Weekly cisplatin at 40 mg/m² combined with definitive RT produced favorable long-term disease control in this real-world cohort of p16-positive oropharyngeal cancer, including patients living in remote regions. However, the absence of a high-dose cisplatin control arm and incomplete comparative toxicity assessment mean these findings support the feasibility of weekly treatment rather than proving equivalent efficacy or improved tolerability.

SOURCE

Cancers

Browse more research Suggest a correction